Economic impact of treating invasive mold disease with isavuconazole compared with liposomal amphotericin B in the UK
| Autor: | Emma Bagshaw, J Posthumus, D. Kuessner, Michael Blackney, David A Enoch |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Microbiology (medical) Drug Posaconazole medicine.medical_specialty Antifungal Agents economic Pyridines media_common.quotation_subject 030106 microbiology Disease invasive fungal infection Aspergillosis mucormycosis Microbiology Drug Costs 03 medical and health sciences Amphotericin B invasive mold disease Nitriles cost Humans Medicine liposomal amphotericin B Intensive care medicine health care economics and organizations media_common Voriconazole business.industry isavuconazole Mucormycosis healthcare Health Care Costs Triazoles medicine.disease United Kingdom posaconazole Models Economic Treatment Outcome Costs and Cost Analysis Liposomal amphotericin business Research Article medicine.drug Healthcare system |
| Zdroj: | Future Microbiology |
| ISSN: | 1746-0921 1746-0913 |
| Popis: | Aim: Invasive mold diseases (IMDs) are associated with significant morbidity and mortality. Approved treatments include voriconazole (VORI), liposomal amphotericin B (L-AMB), posaconazole (POSA) and isavuconazole (ISAV). A UK-based economic model was developed to explore the cost of treating IMDs with ISAV versus L-AMB followed by POSA. Materials & methods: As indirect comparisons have demonstrated similar efficacy between the comparators, a cost-minimization approach was taken. Drug acquisition, administration & monitoring, and hospitalization costs were evaluated from the healthcare system perspective. Results: Per-patient costs were UK£14,842 with ISAV versus UK£18,612 with L-AMB followed by POSA. Savings were driven by drug acquisition, and administration & monitoring costs. Conclusion: ISAV has the potential to reduce IMD treatment costs relative to L-AMB followed by POSA. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|